- Home
- CGTX vs CTOR Comparison
CGTX vs CTOR Comparison
Compare CGTX & CTOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGTX
- CTOR
- Stock Information
- Founded
- CGTX 2007
- CTOR 2021
- Country
- CGTX United States
- CTOR United States
- Employees
- CGTX 25
- CTOR N/A
- Industry
- CGTX Biotechnology: Pharmaceutical Preparations
- CTOR
- Sector
- CGTX Health Care
- CTOR
- Exchange
- CGTX Nasdaq
- CTOR NYSE
- Market Cap
- CGTX 53.4M
- CTOR 63.7M
- IPO Year
- CGTX 2021
- CTOR N/A
- Fundamental
- Price
- CGTX $0.84
- CTOR $1.97
- Analyst Decision
- CGTX Strong Buy
- CTOR Buy
- Analyst Count
- CGTX 4
- CTOR 2
- Target Price
- CGTX $2.83
- CTOR $6.00
- AVG Volume (30 Days)
- CGTX 19.4M
- CTOR 3.1M
- Earning Date
- CGTX 08-07-2025
- CTOR 08-11-2025
- Dividend Yield
- CGTX N/A
- CTOR N/A
- EPS Growth
- CGTX N/A
- CTOR N/A
- EPS
- CGTX N/A
- CTOR N/A
- Revenue
- CGTX N/A
- CTOR N/A
- Revenue This Year
- CGTX N/A
- CTOR N/A
- Revenue Next Year
- CGTX N/A
- CTOR N/A
- P/E Ratio
- CGTX N/A
- CTOR N/A
- Revenue Growth
- CGTX N/A
- CTOR N/A
- 52 Week Low
- CGTX $0.22
- CTOR $0.55
- 52 Week High
- CGTX $2.54
- CTOR $49.00
- Technical
- Relative Strength Index (RSI)
- CGTX 72.32
- CTOR N/A
- Support Level
- CGTX $0.55
- CTOR N/A
- Resistance Level
- CGTX $0.87
- CTOR N/A
- Average True Range (ATR)
- CGTX 0.10
- CTOR 0.00
- MACD
- CGTX 0.02
- CTOR 0.00
- Stochastic Oscillator
- CGTX 61.76
- CTOR 0.00
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
About CTOR CITIUS ONCOLOGY INC
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.